

Index

- Advantages and disadvantages of tests for funnel plot asymmetry 107
- Adverse treatment effects 25
- Allocation 67, 107, 275, 295
- Availability bias 277–8
- Available-case analysis 229, 230
- Bayesian estimation 156
- Bayesian methods 156
- Begg and Mazumdar 100, 105, 142, 195
- Begg and Mazumdar's rank correlation method 100
- (Begg's) rank correlation test 4, 99, 100, 103, 134, 195
- Bias 2, 6, 41, 51, 102, 214, 280, 294, 311
- Biased reporting of outcomes 25, 27
- Binary outcomes 82, 86
- Biological Sciences 183
- Buck's regression method 230
- C2-SPECTR 39, 51, 57, 189
- Campbell Collaboration 39, 52, 57, 189
- Campbell database of systematic reviews (C2-SPECTR) 39, 51, 189
- Categorical data 266
- Censoring 266, 276, 332
- Cochrane 6, 17, 18, 22, 47, 49, 51, 52, 60, 61, 66, 129, 134, 137, 177, 178, 180, 182, 189, 208, 216, 220, 250, 252, 335, 336, 337, 340, 341, 343, 344
- Cochrane Central Register of Controlled Trials 51, 57
- Cochrane Collaboration 51, 66, 129, 208, 216
- Cochrane database of systematic reviews 177, 180
- Combined significance test 121
- Competing interests 304, 305–7, 308, 309–11, 313
- Competing interests (conflicts of interest) 305, 308, 313
- Complete-case analysis 229
- Comprehensive Meta Analysis 200, 215, 243
- Computer programs 194, 198, 200
- Concealment 67, 107, 272, 295
- Control rate effects 293
- Cumulative meta analysis 198, 247 *passim*, 289
- Current Controlled Trials metaRegister and Links Register 38
- DARE (Database of Abstracts of Reviews of Effects) 179, 183
- Data checking 268, 272, 283
- Data suppression 303 *passim*
- Diagnostic Tests 182, 293, 303
- Differential availability of trial data 277
- Differential exclusion of patients 273
- Differential follow up 275
- Direct communication with trialists 271
- Discrepancy between trials and meta-analyses 186
- Dissemination bias 3
- Domain 6, 176, 254, 295
- Domain-wide plot 254
- Drug efficacy 305
- Drug safety 307
- Duplicate publication bias 264, 270
- Duval and Tweedie 130, 133, 197, 203, 207, 304
- Early stopping 291
- Effect size 132, 146 *passim*, 197, 242, 249

- Effect size model 146, 157, 162, 166, 169
- Egger's linear regression method 101
- (Egger's) regression test 85, 101, 105, 128, 134, 196
- Environmental exposures 308
- Environmental Tobacco Smoke 24, 91, 92, 162, 163, 165, 248
- Ethics 19, 21, 186, 288, 312
- Evolution of effect sizes and chance 244
- heterogeneity 243
- publication bias 243
- safety outcomes 257
- time-lag bias 242
- Evolving study populations 296
- Example datasets
- interview and job performance 56, 140, 329
- passive smoking 55, 108, 115, 139, 141, 199, 246
- teacher expectancy 56, 108, 115, 172, 246, 321
- Fail safe N 5, 111 *passim*, 196, 212, 214
- File-drawer analysis 5
- File drawer problem 112, 123
- First versus subsequent evidence 246, 247
- Fisher failsafe N 120, 122
- Fixed effects model 117, 134, 146, 147, 155, 169, 246
- Follow up bias 275
- Forest plot 194, 200 *passim*, 324
- Funding source
- industry funding 18, 21, 24–5, 313
- Funnel asymmetry 183, 184, 188, 189
- Funnel plot 75 *passim*, 129, 131, 133, 139, 161, 172, 180, 194, 201 *passim*, 233, 292, 296, 343
- Funnel plot asymmetry 4, 77, 85, 88, 90, 103, 105, 131, 139, 296
- Funnel plots for studies with binary outcomes 82
- Funnel plots for studies with numerical outcomes 87
- GlaxoSmithKline 1
- Gleser and Olkin method 118, 122, 128
- Grey literature 4, 18, 24, 26, 49 *passim*, 267, 268, 271, 283, 338, 339–40, 344
- Hazard ratios 65, 268, 269, 274, 275
- Heterogeneity 64, 82, 243, 296, 297, 298
- Heterogeneity in study populations 296
- Hot deck imputation 230
- Imputation techniques 5, 227
- Inclusion of inappropriate studies 271
- Individual patient data 47, 65, 225, 262, 276, 298
- Individual patient data meta-analysis 64, 225, 262
- Information retrieval 4, 53, 334
- Initial versus subsequent evidence 242, 244, 246
- Intention-to-treat 229, 231, 236, 273
- IPD deciding if obtaining is likely to be helpful 279
- IPD meta-analyses 262 *passim*, 336–7
- IPD meta-analyses in healthcare 263
- IPD meta-analyses in the social sciences and education 263
- IPD meta-analyses publication and time-lag bias of 280
- IPD using to explore bias 264
- Journal editors 66, 304, 335
- Language biases 187
- Likelihood 13, 22, 148, 152, 154, 155
- Likelihood ratio test 150, 156, 163, 167, 170
- Maximum likelihood estimation 151, 152, 156
- Maximum likelihood methods 230
- Mean substitution 229, 341
- Merck 1
- Meta-analysis 2 *passim*, 36, 41, 46, 92, 93, 94, 95, 108, 129, 158, 194, 198, 215, 225 *passim*, 247, 253, 254, 262, 264, 267 *passim*, 292, 295, 298, 329
- Meta-analysis models
- fixed effect 82, 83, 134, 178, 348
- random effect 82, 134, 141, 178, 195, 321, 337, 349, 350
- Meta-experiment 42, 45, 47
- Meta-regression 102, 107, 109, 293
- Meta-regression to examine small study effects 102
- MetaWin 211
- Missing at random (MAR) 226, 228
- Missing completely at random (MCAR) 226, 228, 230
- Missing data 5, 148, 166, 224 *passim*, 341, 342
- mechanisms 227
- Multiple imputation 227, 229, 230
- Multiple publications 270

- Negative results 14, 16, 17, 23, 24, 26, 163, 288, 290
- Not missing at random (NMAR) 227
- Null Bias 294
- Omitted research 311
- Orwin's fail safe N 119, 197, 202, 212, 214
- Orwin's N 119
- Outcome reporting bias 225, 234, 277
- p -value 149, 152, 162, 164, 166, 168, 171, 252, 275
- Pairwise deletion, *see* Available-case analysis
- Patient exclusion bias 273
- Paxil 2
- Peer review 225, 268
- Pharmaceutical company 64, 305
- Phonics programs 225
- Pipeline bias 280
- Placebo controls 14, 42, 45, 82, 177, 250, 311
- Political agendas 310
- Positive results 14, 16, 17, 18, 22, 24, 25, 26, 63, 90, 104, 123, 129, 270, 288, 299, 304
- Prospective meta-analyses 4, 35–6, 41, 45, 262, 267, 271, 338
- Prospective Pravastatin Pooling Project 42
- Publication bias 1 *passim*, 14, 15, 17, 26, 37, 51, 76, 129, 131, 133, 177, 179, 182, 189, 199, 215, 243, 261, 267, 269, 270, 288, 291, 293, 295, 296, 313, 334
- as threat to validity 1–3, 27, 160, 189
- direct evidence of 176
- emerging issues in 5
- empirical investigations of 5, 176, 186, 225
- history of 4, 128
- impact of 114–115, 176, 338
- indirect evidence of 177
- reasons for 3, 6, 21, 38, 45, 107, 129
- software for 128, 193 *passim*
- Quality of data from unpublished sources 268
- Quasi random methods 271
- Random allocation 273
- Random effects model 94, 133, 134, 138, 147, 162, 200, 246, 249, 255, 256
- Randomised Controlled Trials (RCTs) 177, 179, 186, 190, 236, 268
- Rank correlation test 106, 108, 183, 195, 196, 202, 214
- Recursive cumulative meta-analysis (RCM) 242, 249, 252, 253, 254
- Register 27, 54
- Registers 13, 27, 54, 59
- Registries 37
- Regression-based test 128
- Regression test 101, 108, 185
- Regression to the mean 106, 108, 178
- Relapse prevention 256, 346
- Relative changes in the effect size 6, 184, 187, 195, 242, 253
- Reporting bias 17, 188, 225, 234, 277
- RevMan 208
- Robustness of weight function methods 159
- (Rosenthal's) fail safe N 111, 112, 113, 117, 119, 120, 121, 122, 183, 196
- Ruptured abdominal aortic aneurysm repair (RAAA) 232
- Selection bias 146, 271
- Selection model 5, 103, 107, 118, 146 *passim*, 190, 217, 231, 234, 333, 335, 337, 345
- Selective citation 26
- Selective reporting of outcomes 25, 277
- Sensitivity analysis 134, 232, 236, 237, 278
- Small study effects 75, 90, 102
- Software 200
- Sources of funnel plot asymmetry 88
- Sponsorship 307
- SSRI anti depressants 1
- STATA 205
- Statistical methods
- assessing funnel asymmetry 76, 188
- for assessing publication bias 76, 177
- Statistical power 24, 44, 270
- Statistical tests
- and power of 340, 349
- Step function (as weight function) 149, 169
- Stouffer's test 113
- Stratified analysis 268
- Study design effects 295
- Study termination 305, 306
- Subgroup analyses 24, 42, 224, 228, 282, 389
- Systematic review 2, 17, 36, 51 *passim*, 183, 232, 267, 271

- Teacher expectancy effects 92, 141, 169
- Tests for publication bias 133, 294
- Time-dependent effects 291
- Time-dependent outcomes 276
- Time lag bias 51, 54, 186–7, 242, 243, 244, 252, 280, 288, 289, 290, 291, 299
- Time-lag biases 186
- Time-to-event analyses 268, 282
- Time to publication 22, 186, 242, 281, 288, 338
- Timing of follow up and reporting 22, 243, 265, 336
- Treatment effects 63, 76, 83, 87, 104, 187, 244, 249, 255, 291
- Trial registry 37
- Trim and Fill 5, 107, 127 *passim*, 161, 178, 179, 182, 183, 184, 185, 187, 189, 194, 197, 198, 199, 200, 202, 203, 205, 207, 214, 215, 231, 234, 339 *passim*
- Trim and Fill method 5, 129, 130, 233
- Unpublished literature 4, 55
- Unpublished trials 17, 66, 267
- Vioxx 1
- Weight function 149 *passim*, 254
- Weight functions, a priori 164, 165, 168, 171
- Weight functions, that depend on both T and σ 149, 157, 160
- Weight functions, that depend only on the p-value 149, 152, 164, 168, 171
- Weighted distribution 147, 151
- What Works Clearinghouse 39

